#1 Clinical Trials Search in Europe

Mumps Virus Jeryl Lynn (Level B) Strain (Live, Attenuated) Produced In Chick Embryo Cells

This article examines several clinical trials investigating the use of the Mumps Virus Jeryl Lynn (Level B) Strain vaccine, a component of the measles, mumps, and rubella (MMR) vaccine. These studies explore the vaccine’s effectiveness, safety, and immune responses in different populations, including children, adults with chronic obstructive pulmonary disease (COPD), and infants during measles outbreaks. The trials aim to improve our understanding of vaccine-induced immunity and potential non-specific effects of live vaccines.

Table of Contents

What is MUMPS VIRUS JERYL LYNN (LEVEL B) STRAIN?

MUMPS VIRUS JERYL LYNN (LEVEL B) STRAIN is a live, attenuated virus used in vaccines to prevent mumps infection. It is produced in chick embryo cells, which means the virus is grown in eggs before being weakened (attenuated) for use in vaccines[1]. This strain is a key component of combination vaccines that protect against multiple diseases, such as measles, mumps, and rubella (MMR) or measles, mumps, rubella, and varicella (MMRV) vaccines[1].

How Does It Work?

As a live, attenuated vaccine, the MUMPS VIRUS JERYL LYNN (LEVEL B) STRAIN works by introducing a weakened form of the mumps virus into the body. This stimulates the immune system to produce antibodies against the virus without causing the full-blown disease. When a person later encounters the real mumps virus, their immune system is prepared to fight it off, preventing infection or reducing its severity[1].

What Is It Used For?

The primary use of this vaccine component is to prevent mumps infection. It is typically included in combination vaccines that offer protection against multiple diseases:

  • MMR (Measles, Mumps, Rubella) vaccine
  • MMRV (Measles, Mumps, Rubella, Varicella) vaccine
These vaccines are routinely given to children as part of national immunization programs in many countries[2]. They may also be administered to adults who haven’t been previously vaccinated or who require additional protection.

How Is It Administered?

The vaccine containing MUMPS VIRUS JERYL LYNN (LEVEL B) STRAIN is typically administered as an injection. The specific route of administration may vary depending on the vaccine formulation:

  • Subcutaneous injection (under the skin)[1]
  • Intramuscular injection (into the muscle)[2]
The dosage and schedule can vary depending on the specific vaccine and the country’s immunization guidelines. Generally, children receive two doses of MMR or MMRV vaccine, with the first dose given between 12-15 months of age and the second dose between 4-6 years of age[1].

Safety and Side Effects

Vaccines containing MUMPS VIRUS JERYL LYNN (LEVEL B) STRAIN are generally considered safe and effective. However, like all medical interventions, they can have side effects. Common side effects may include:

  • Soreness or redness at the injection site
  • Mild fever
  • Rash
  • Temporary joint pain (more common in adults, especially women)
Serious side effects are rare but can include severe allergic reactions. It’s important to discuss any concerns or potential contraindications with a healthcare provider before receiving the vaccine[1].

Current Research and Clinical Trials

Several ongoing clinical trials are exploring new applications or formulations of vaccines containing MUMPS VIRUS JERYL LYNN (LEVEL B) STRAIN:

  • A Phase II study is evaluating the immunogenicity and safety of a new MMRV vaccine formulation in children aged 4 to 6 years[1].
  • Another study is investigating the potential of epicutaneous (on the skin) administration of MMR vaccine compared to the standard injection method[3].
  • Researchers are also exploring the use of MMR vaccine to induce beneficial innate immune training in patients with chronic obstructive pulmonary disease (COPD)[4].
  • A trial is assessing the effectiveness of early MMR vaccination (between 6 and 12 months of age) during measles outbreaks[2].
These studies aim to improve our understanding of the vaccine’s effects, explore new administration methods, and potentially expand its applications beyond traditional use.

Study Focus Population Key Objectives Notable Aspects
Immunogenicity and safety of MMRV vaccine Healthy children 4-6 years old Evaluate immune response and safety of different MMRV formulations Comparing investigational vaccines to ProQuad
Epicutaneous MMR vaccination Adults 18-34 years old Compare mucosal immune response of skin application vs. injection Novel administration method for potential improved immunity
Live vaccines in COPD patients Adults with COPD Assess effects on innate immune training and systemic inflammation Exploring non-specific beneficial effects of live vaccines
Early MMR vaccination during outbreaks Infants 6-12 months old Evaluate immune response to early MMR-0 immunization Investigating protection strategies for young infants during outbreaks

FAQ

  • What is the Mumps Virus Jeryl Lynn (Level B) Strain vaccine? The Mumps Virus Jeryl Lynn (Level B) Strain vaccine is a live, attenuated (weakened) virus produced in chick embryo cells. It is one of the components of the combined measles, mumps, and rubella (MMR) vaccine used to prevent these diseases.
  • What age groups are being studied in these clinical trials? The clinical trials involve various age groups, including children aged 4-6 years, adults with COPD, and infants as young as 6 months old during measles outbreaks.
  • Are there any new ways of administering the MMR vaccine being tested? Yes, one study is exploring epicutaneous vaccination (applying the vaccine to the skin) with the MMR vaccine to see if it generates appropriate mucosal immune responses compared to standard injection methods.
  • What are some of the main objectives of these clinical trials? The main objectives include evaluating the immune response to the vaccine, assessing its safety and reactogenicity, comparing different vaccine formulations, and investigating potential non-specific effects of live vaccines on the immune system.
  • Are there any studies looking at early MMR vaccination during outbreaks? Yes, one study is investigating the immune response to an early extra MMR vaccination (MMR-0) given to infants younger than 12 months during a measles outbreak, compared to the standard vaccination schedule.

Ongoing Clinical Trials on Mumps Virus Jeryl Lynn (Level B) Strain (Live, Attenuated) Produced In Chick Embryo Cells

  • Evaluating measles, mumps, rubella vaccine (live) in lactating women to enhance infant mucosal immunity

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Belgium

  • Study on Early Measles Immunization with MMR-0 Vaccine for Infants Under 12 Months During a Measles Outbreak

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Immune Response and Safety of Measles, Mumps, Rubella, and Varicella Vaccine in Healthy Children Aged 4 to 6 Years

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Latvia Spain

  • Study on the Effectiveness of Skin Patch Vaccination with Measles, Mumps, and Rubella Vaccine in Healthy Volunteers

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on the Effects of Live Vaccines (Measles, Mumps, Rubella, BCG) on Immune System in Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    2 1 1
    Investigated drugs:
    Denmark

Glossary

  • Attenuated vaccine: A vaccine containing a weakened form of a virus or bacteria that can still produce an immune response without causing the full-blown disease.
  • Epicutaneous vaccination: A method of vaccine administration where the vaccine is applied to the skin surface rather than injected.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Reactogenicity: The capacity of a vaccine to produce common, expected adverse reactions, usually mild and self-limited, such as pain at injection site or fever.
  • Seroresponse: The development of antibodies in the blood in response to vaccination or infection.
  • Geometric Mean Concentration (GMC): A type of average used to measure antibody levels in a group of individuals after vaccination.
  • Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases that cause airflow blockage and breathing-related problems.
  • Innate immune training: A process where the innate immune system develops enhanced responsiveness to subsequent infections or stimuli following exposure to certain pathogens or vaccines.
  • Maternal antibodies: Antibodies passed from mother to infant during pregnancy or through breast milk, providing temporary immunity to the newborn.
  • Plaque Reduction Neutralization Test (PRNT): A laboratory test used to measure the concentration of neutralizing antibodies in a person's blood.

References

  1. http://clinicaltrials.eu/trial-id/2022-501564-18-00
  2. http://clinicaltrials.eu/trial-id/2024-513395-18-00
  3. http://clinicaltrials.eu/trial-id/2023-503845-79-01
  4. http://clinicaltrials.eu/trial/study-on-the-effects-of-live-vaccines-measles-mumps-rubella-bcg-on-immune-system-in-patients-with-chronic-obstructive-pulmonary-disease-copd/